Literature DB >> 26242242

Optimization of N-aryl-6-methoxy-1,2,3,4-tetrahydroquinolines as tubulin polymerization inhibitors.

Sheng-Biao Wang1, Xiao-Feng Wang1, Bingjie Qin1, Emika Ohkoshi2, Kan-Yen Hsieh3, Ernest Hamel4, Mu-Tian Cui1, Dong-Qing Zhu1, Masuo Goto2, Susan L Morris-Natschke2, Kuo-Hsiung Lee5, Lan Xie6.   

Abstract

Thirteen new N-aryl 1,2,3,4-tetrahydroquinoline compounds (4a-f, 6a-c, and 8a-d) were synthesized and evaluated for antitumor activity and drug-like properties. Compound 4a exhibited high inhibitory potency with low nanomolar GI50 values of 16-20 nM in cellular assays, including excellent activity against the P-glycoprotein overexpressing cell line KBvin. Compound 4a inhibited colchicine binding to tubulin and tubulin assembly with an IC50 value of 0.85 μM, superior to the reference compound CA4 (1.2 μM) in the same assay. In addition, 4a also exhibited highly improved water solubility (75 μg/mL) and a suitable logP value (3.43) at pH 7.4. With a good balance between antitumor potency and drug-like properties, compound 4a could be a new potential drug candidate for further development. Current results on SAR studies and molecular modeling provided more insight about this class of compounds as tubulin polymerization inhibitors targeting the colchicine site.
Copyright © 2015 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Colchicine binding inhibitors; Cytotoxic activity; N-Aryl 1,2,3,4-tetrahydroquinolines; Tubulin polymerization inhibitors

Mesh:

Substances:

Year:  2015        PMID: 26242242      PMCID: PMC4554882          DOI: 10.1016/j.bmc.2015.07.016

Source DB:  PubMed          Journal:  Bioorg Med Chem        ISSN: 0968-0896            Impact factor:   3.641


  25 in total

Review 1.  Evaluation of antimitotic agents by quantitative comparisons of their effects on the polymerization of purified tubulin.

Authors:  Ernest Hamel
Journal:  Cell Biochem Biophys       Date:  2003       Impact factor: 2.194

2.  Insight into tubulin regulation from a complex with colchicine and a stathmin-like domain.

Authors:  Raimond B G Ravelli; Benoît Gigant; Patrick A Curmi; Isabelle Jourdain; Sylvie Lachkar; André Sobel; Marcel Knossow
Journal:  Nature       Date:  2004-03-11       Impact factor: 49.962

Review 3.  Disrupting tumour blood vessels.

Authors:  Gillian M Tozer; Chryso Kanthou; Bruce C Baguley
Journal:  Nat Rev Cancer       Date:  2005-06       Impact factor: 60.716

4.  Feasibility of a high-flux anticancer drug screen using a diverse panel of cultured human tumor cell lines.

Authors:  A Monks; D Scudiero; P Skehan; R Shoemaker; K Paull; D Vistica; C Hose; J Langley; P Cronise; A Vaigro-Wolff
Journal:  J Natl Cancer Inst       Date:  1991-06-05       Impact factor: 13.506

5.  Structure-activity analysis of the interaction of curacin A, the potent colchicine site antimitotic agent, with tubulin and effects of analogs on the growth of MCF-7 breast cancer cells.

Authors:  P Verdier-Pinard; J Y Lai; H D Yoo; J Yu; B Marquez; D G Nagle; M Nambu; J D White; J R Falck; W H Gerwick; B W Day; E Hamel
Journal:  Mol Pharmacol       Date:  1998-01       Impact factor: 4.436

6.  Discovery of N-(4-methoxyphenyl)-N,2-dimethylquinazolin-4-amine, a potent apoptosis inducer and efficacious anticancer agent with high blood brain barrier penetration.

Authors:  Nilantha Sirisoma; Azra Pervin; Hong Zhang; Songchun Jiang; J Adam Willardsen; Mark B Anderson; Gary Mather; Christopher M Pleiman; Shailaja Kasibhatla; Ben Tseng; John Drewe; Sui Xiong Cai
Journal:  J Med Chem       Date:  2009-04-23       Impact factor: 7.446

7.  Comparison of in vitro anticancer-drug-screening data generated with a tetrazolium assay versus a protein assay against a diverse panel of human tumor cell lines.

Authors:  L V Rubinstein; R H Shoemaker; K D Paull; R M Simon; S Tosini; P Skehan; D A Scudiero; A Monks; M R Boyd
Journal:  J Natl Cancer Inst       Date:  1990-07-04       Impact factor: 13.506

8.  The sulphorhodamine (SRB) assay and other approaches to testing plant extracts and derived compounds for activities related to reputed anticancer activity.

Authors:  Peter Houghton; Rui Fang; Isariya Techatanawat; Glyn Steventon; Peter J Hylands; C C Lee
Journal:  Methods       Date:  2007-08       Impact factor: 3.608

Review 9.  Anti-mitotic activity of colchicine and the structural basis for its interaction with tubulin.

Authors:  Bhabatarak Bhattacharyya; Dulal Panda; Suvroma Gupta; Mithu Banerjee
Journal:  Med Res Rev       Date:  2008-01       Impact factor: 12.944

10.  A phase I pharmacokinetic and translational study of the novel vascular targeting agent combretastatin a-4 phosphate on a single-dose intravenous schedule in patients with advanced cancer.

Authors:  Afshin Dowlati; Kelly Robertson; Matthew Cooney; William P Petros; Michael Stratford; John Jesberger; Niusha Rafie; Beth Overmoyer; Vinit Makkar; Bruce Stambler; Anne Taylor; John Waas; Jonathan S Lewin; Keith R McCrae; Scot C Remick
Journal:  Cancer Res       Date:  2002-06-15       Impact factor: 12.701

View more
  5 in total

1.  Scaffold Hopping-Driven Optimization of 4-(Quinazolin-4-yl)-3,4-dihydroquinoxalin-2(1H)-ones as Novel Tubulin Inhibitors.

Authors:  Li Jiang; Masuo Goto; Dong-Qing Zhu; Pei-Ling Hsu; Kang-Po Li; Mutian Cui; Xiaoyang He; Susan Lynne Morris-Natschke; Kuo-Hsiung Lee; Lan Xie
Journal:  ACS Med Chem Lett       Date:  2019-12-30       Impact factor: 4.345

2.  Synthesis, biological evaluation, and physicochemical property assessment of 4-substituted 2-phenylaminoquinazolines as Mer tyrosine kinase inhibitors.

Authors:  Sheng-Biao Wang; Mu-Tian Cui; Xiao-Feng Wang; Emika Ohkoshi; Masuo Goto; De-Xuan Yang; Linna Li; Shoujun Yuan; Susan L Morris-Natschke; Kuo-Hsiung Lee; Lan Xie
Journal:  Bioorg Med Chem       Date:  2016-05-17       Impact factor: 3.641

3.  X-ray Crystallography-Guided Design, Antitumor Efficacy, and QSAR Analysis of Metabolically Stable Cyclopenta-Pyrimidinyl Dihydroquinoxalinone as a Potent Tubulin Polymerization Inhibitor.

Authors:  Souvik Banerjee; Foyez Mahmud; Shanshan Deng; Lingling Ma; Mi-Kyung Yun; Sayo O Fakayode; Kinsie E Arnst; Lei Yang; Hao Chen; Zhongzhi Wu; Pradeep B Lukka; Keyur Parmar; Bernd Meibohm; Stephen W White; Yuxi Wang; Wei Li; Duane D Miller
Journal:  J Med Chem       Date:  2021-08-18       Impact factor: 8.039

4.  Potential of substituted quinazolines to interact with multiple targets in the treatment of cancer.

Authors:  Shruti Choudhary; Arpit Doshi; Lerin Luckett-Chastain; Michael Ihnat; Ernest Hamel; Susan L Mooberry; Aleem Gangjee
Journal:  Bioorg Med Chem       Date:  2021-02-12       Impact factor: 3.641

Review 5.  Molecular targets and anticancer activity of quinoline-chalcone hybrids: literature review.

Authors:  Mamdouh F A Mohamed; Gamal El-Din A Abuo-Rahma
Journal:  RSC Adv       Date:  2020-08-21       Impact factor: 4.036

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.